Opportunity remains for private “accredited investors” to invest in
BioActive Therapeutics, Inc. Contact BioActive by phone or email to
discuss your investment interests.
- What is at stake? Consider the following: Tissue healing
and chronic wound care is one of the fastest growing sectors of the
healthcare industry. In the US there are over 100 million surgeries
performed annually and roughly 7 million people suffer from chronic
- Platelet-gel improves healing outcomes over traditional healing
modalities such as wound vacs and single growth factor or fibrogen
treatments. Cost savings result from improved outcomes.
- With rapidly increasing diabetic and elderly patients,
the incidence of venous and diabetic ulcers and pressure sores will
continue to rise along with surgeries, driving demand for the tissue
healing solutions BioActive provides.
- Couple that with multiple years of double-digit healthcare
inflation projected to continue and you have a market primed and
ready for those who bring cost-saving yet highly viable solutions to